HEADER RECORD*******LIBRARY HEADER RECORD!!!!!!!000000000000000000000000000000 SAS SAS SASLIB 9.4 X64_SR12 18JUN21:06:47:1618JUN21:06:47:16 HEADER RECORD*******MEMBER HEADER RECORD!!!!!!!000000000000000001600000000140 HEADER RECORD*******DSCRPTR HEADER RECORD!!!!!!!000000000000000000000000000000 SAS FAAE SASDATA 9.4 X64_SR12 18JUN21:06:47:1618JUN21:06:47:16 Findings About Events or Interventions HEADER RECORD*******NAMESTR HEADER RECORD!!!!!!!000000002700000000000000000000 STUDYID Study Identifier DOMAIN Domain Abbreviation USUBJID Unique Subject Identifier FASEQ Sequence Number )FALNKGRPLink Group ID 1FATESTCDFindings About Test Short Name 5$FATEST Findings About Test Name ='FAOBJ Object of the Observation a FACAT Category for Findings About  FASCAT Subcategory for Findings About ^ FAORRES Result or Finding in Original Units  FAORRESUOriginal Units  ^ FASTRESCCharacter Result/Finding in Std Format  FASTRESNNumeric Result/Finding in Standard Units jFASTRESUStandard Units rFASTAT Completion Status t1FALOC Location of the Finding About | FAEVAL Evaluator VISITNUMVisit Number EPOCH Epoch FADTC Date/Time of Collection FADY Study Day of Collection 1FATPT Planned Time Point Name FATPTNUMPlanned Time Point Number "FATPTREFTime Point Reference *FARFTDTCDate/Time of Reference Time Point 0FAEVLINTEvaluation Interval @ HEADER RECORD*******OBS HEADER RECORD!!!!!!!000000000000000000000000000000 mRNA-1273-P201FAmRNA-1273-P201-US201-1007A1040LDIAM Longest Diameter Erythema REACTOGENICITY ADMINISTRATION SITE3 mm3 A0mm STUDY SUBJECT.BLINDED TREATMENT 2020-06-08T18:13 ADAY 8 ADOSE 12020-06-01T14:47-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1007A 1040LDIAM Longest Diameter Erythema REACTOGENICITY ADMINISTRATION SITE1 mm1 Amm STUDY SUBJECT.BLINDED TREATMENT 2020-06-09T18:29 ADAY 9 ADOSE 12020-06-01T14:47-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1007A01040OCCUR Occurrence Indicator Erythema REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-06-08T18:13 ADAY 8 ADOSE 12020-06-01T14:47-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1007A@1040OCCUR Occurrence Indicator Erythema REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-06-09T18:29 ADAY 9 ADOSE 12020-06-01T14:47-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1007AP1040OCCUR Occurrence Indicator Erythema REACTOGENICITY ADMINISTRATION SITEN N . STUDY SUBJECT.BLINDED TREATMENT 2020-06-10T18:13 ADAY 10 ADOSE 12020-06-01T14:47-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1007A`1040SEV Severity/Intensity Erythema REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-08T20:00 ADAY 8 ADOSE 12020-06-01T14:47-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1007Ap1040SEV Severity/Intensity Erythema REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-09T20:00 ADAY 9 ADOSE 12020-06-01T14:47-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1007A1040SEV Severity/Intensity Erythema REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-10 ADAY 10 ADOSE 12020-06-01T14:47-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1043A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-08T12:01 ADAY 8 ADOSE 12020-06-01T09:07-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1056A1040OCCUR Occurrence Indicator Erythema REACTOGENICITY ADMINISTRATION SITEN N . STUDY SUBJECT.BLINDED TREATMENT 2020-06-09T16:02 ADAY 8 ADOSE 12020-06-02T17:52-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1060A1130OCCUR Occurrence Indicator Rash REACTOGENICITY SYSTEMIC Y Y . STUDY SUBJECT.BLINDED TREATMENT 2020-06-09T19:01 ADAY 8 ADOSE 12020-06-02T12:40-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1060A 1130OCCUR Occurrence Indicator Rash REACTOGENICITY SYSTEMIC Y Y . STUDY SUBJECT.BLINDED TREATMENT 2020-06-10T19:28 ADAY 9 ADOSE 12020-06-02T12:40-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1060A01130OCCUR Occurrence Indicator Rash REACTOGENICITY SYSTEMIC Y Y . STUDY SUBJECT.BLINDED TREATMENT 2020-06-11T23:02 ADAY 10 ADOSE 12020-06-02T12:40-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1060A@1130OCCUR Occurrence Indicator Rash REACTOGENICITY SYSTEMIC N N . STUDY SUBJECT.BLINDED TREATMENT 2020-06-12T22:52 ADAY 11 ADOSE 12020-06-02T12:40-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1067A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 12020-06-03T13:35-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1067A 1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 12020-06-03T13:35-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1067A01070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 12020-06-03T13:35-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1067A@1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 12020-06-03T13:35-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1067AP1110SEV Severity/Intensity Nausea/Vomiting REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 12020-06-03T13:35-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1067A`1110SEV Severity/Intensity Nausea/Vomiting REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 12020-06-03T13:35-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068A2050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE10 mm10 Amm STUDY SUBJECT.BLINDED TREATMENT 2020-07-07T23:21 B$DAY 8 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068A 2050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE10 mm10 Amm STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T23:48 B%DAY 9 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068A02050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE10 mm10 Amm STUDY SUBJECT.BLINDED TREATMENT 2020-07-10T00:10 B'DAY 10 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068A@2050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-07T23:21 B$DAY 8 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068AP2050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T23:48 B%DAY 9 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068A`2050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-10T00:10 B'DAY 10 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068Ap2050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEN N . STUDY SUBJECT.BLINDED TREATMENT 2020-07-11T00:00 B(DAY 11 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068A2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-07T14:00 B$DAY 8 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068A2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEDOES NOT INTERFERE WITH ACTIVITY DOES NOT INTERFERE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-07T23:21 B$DAY 8 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068A2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-08T14:00 B%DAY 9 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068A2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEDOES NOT INTERFERE WITH ACTIVITY DOES NOT INTERFERE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T23:48 B%DAY 9 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068A2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-09T14:00 B&DAY 10 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068A2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEDOES NOT INTERFERE WITH ACTIVITY DOES NOT INTERFERE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-10T00:09 B'DAY 10 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068A2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-10T23:00 B'DAY 11 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068A2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEDOES NOT INTERFERE WITH ACTIVITY DOES NOT INTERFERE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-11T00:00 B(DAY 11 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068B2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITENONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-11T23:22 B(DAY 12 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068B2050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-07 B$DAY 8 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068B2050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-08 B%DAY 9 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068B2050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-09 B&DAY 10 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068B2050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-10 B'DAY 11 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068B2050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-11 B(DAY 12 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068B2050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-12 B)DAY 13 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068B2050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-13 B*DAY 14 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068B2050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-14 B+DAY 15 ADOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1068B2050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-15 B,DAY 16 BDOSE 22020-06-30T09:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1070A2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITENONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-13T12:00 B'DAY 8 ADOSE 22020-07-06T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1080A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-11T16:25 ADAY 9 ADOSE 12020-06-03T11:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1080A 1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 12020-06-03T11:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1084A2130OCCUR Occurrence Indicator Rash REACTOGENICITY SYSTEMIC Y Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T00:03 B%DAY 8 ADOSE 22020-06-30T08:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1084A 2130OCCUR Occurrence Indicator Rash REACTOGENICITY SYSTEMIC Y Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-09T04:12 B&DAY 9 ADOSE 22020-06-30T08:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1084A02130OCCUR Occurrence Indicator Rash REACTOGENICITY SYSTEMIC Y Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-10T03:55 B'DAY 10 ADOSE 22020-06-30T08:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1084A@2130OCCUR Occurrence Indicator Rash REACTOGENICITY SYSTEMIC N N . STUDY SUBJECT.BLINDED TREATMENT 2020-07-11T02:39 B(DAY 11 ADOSE 22020-06-30T08:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1089A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-12T22:56 ADAY 8 ADOSE 12020-06-05T09:28-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1103A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T14:30 B%DAY 8 ADOSE 22020-07-07T16:08-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1103A 2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T14:30 B%DAY 8 ADOSE 22020-07-07T16:08-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1103A02090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T14:30 B%DAY 8 ADOSE 22020-07-07T16:08-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1122A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-03T18:22 ADAY 8 ADOSE 12020-06-26T08:49-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1122A 1090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-03T18:22 ADAY 8 ADOSE 12020-06-26T08:49-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123A1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-03T20:48 ADAY 8 ADOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123A 1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-04T23:28 ADAY 9 ADOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123A01100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-05T20:25 ADAY 10 ADOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123A@1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-06T21:01 ADAY 11 ADOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123AP1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-07T20:45 ADAY 12 ADOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123A`1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T23:11 ADAY 13 ADOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123Ap1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-09T21:14 ADAY 14 ADOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123A1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-10T20:45 ADAY 15 ADOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123A1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-11T20:45 BDAY 16 BDOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123A1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-12T20:45 BDAY 17 BDOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123A1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-13T20:46 BDAY 18 BDOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123A1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T20:46 BDAY 19 BDOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123A1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-16T06:47 BDAY 20 BDOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123A1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-16T20:15 BDAY 21 BDOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123A1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-17T22:40 BDAY 22 BDOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123B1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-18T20:50 BDAY 23 BDOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123B1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-19T20:45 BDAY 24 BDOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123B1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-20T20:45 BDAY 25 BDOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-31T21:22 B$DAY 8 ADOSE 22020-07-24T16:13-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123B1090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-03T20:47 ADAY 8 ADOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123B1090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-04T23:27 ADAY 9 ADOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123B1090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-05T20:25 ADAY 10 ADOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123B1090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-06T21:01 ADAY 11 ADOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123B1090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-07T20:45 ADAY 12 ADOSE 12020-06-26T16:56-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1123B2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-31 B$DAY 8 ADOSE 22020-07-24T16:13-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1137A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-04T12:50 ADAY 9 ADOSE 12020-06-26T09:14-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1137A 1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 12020-06-26T09:14-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1142A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-07-27T15:42-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1142A 2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-27T15:42-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1142A02090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-07-27T15:42-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1142A@2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-27T15:42-P1DmRNA-1273-P201FAmRNA-1273-P201-US201-1155A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-04T12:45 B$DAY 8 ADOSE 22020-07-28T14:30-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1004A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-05T21:37 ADAY 8 ADOSE 12020-05-29T11:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020A2130OCCUR Occurrence Indicator Rash REACTOGENICITY SYSTEMIC N N . STUDY SUBJECT.BLINDED TREATMENT 2020-07-07T16:05 B%DAY 8 ADOSE 22020-06-30T11:09-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020A 1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-08 ADAY 8 ADOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020A01080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-08T14:37 ADAY 8 ADOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020A@1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-09 ADAY 9 ADOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020AP1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-09T12:50 ADAY 9 ADOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020A`1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-10 ADAY 10 ADOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020Ap1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-10T14:36 ADAY 10 ADOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-11 ADAY 11 ADOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-11T12:06 ADAY 11 ADOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-12 ADAY 12 ADOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-12T12:05 ADAY 12 ADOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-13 ADAY 13 ADOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-13T21:06 ADAY 13 ADOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-14 ADAY 14 ADOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-15 ADAY 15 ADOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020B1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-15T07:46 ADAY 14 ADOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020B1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-15T12:50 ADAY 15 ADOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020B1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-16 BDAY 16 BDOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020B1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-16T12:25 BDAY 16 BDOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020B1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-17T12:34 BDAY 17 BDOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020B1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-08 ADAY 8 ADOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020B1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC REPEATED USE OF OVER-THE-COUNTER PAIN RELIEVER > 24 HOURS OR SOME INTERFERERENCE WITH ACTIVITY REPEATED USE OF OVER-THE-COUNTER PAIN RELIEVER > 24 HOURS OR SOME INTERFERERENCE WITH ACTIVITY. STUDY SUBJECT.BLINDED TREATMENT 2020-06-08T14:37 ADAY 8 ADOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020B1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-09 ADAY 9 ADOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020B1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-09T12:50 ADAY 9 ADOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1020B1030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITENONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-08T14:36 ADAY 8 ADOSE 12020-06-01T12:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1058A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 3/SEVERE GRADE 3/SEVERE . INVESTIGATOR .BLINDED TREATMENT 2020-07-14T22:22 B(DAY 8 ADOSE 22020-07-07T09:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1058A 2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T22:22 B(DAY 8 ADOSE 22020-07-07T09:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1058A02080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 3/SEVERE GRADE 3/SEVERE . INVESTIGATOR .BLINDED TREATMENT 2020-07-14T21:41 B(DAY 8 ADOSE 22020-07-07T09:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1058A@2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T22:22 B(DAY 8 ADOSE 22020-07-07T09:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1058AP2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 3/SEVERE GRADE 3/SEVERE . INVESTIGATOR .BLINDED TREATMENT 2020-07-15T12:00 B)DAY 9 ADOSE 22020-07-07T09:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1058A`2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-15T22:43 B)DAY 9 ADOSE 22020-07-07T09:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1058Ap2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T22:22 B(DAY 8 ADOSE 22020-07-07T09:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1058A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-15T22:43 B)DAY 9 ADOSE 22020-07-07T09:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1058A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 3/SEVERE GRADE 3/SEVERE . INVESTIGATOR .BLINDED TREATMENT 2020-07-14T22:22 B(DAY 8 ADOSE 22020-07-07T09:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1058A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T22:22 B(DAY 8 ADOSE 22020-07-07T09:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1058A2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITENONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T22:22 B(DAY 8 ADOSE 22020-07-07T09:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1080A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-12T21:35 ADAY 8 ADOSE 12020-06-05T15:06-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1080A 1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-12T23:20 ADAY 8 ADOSE 12020-06-05T15:06-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1080A01080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-13T21:35 ADAY 9 ADOSE 12020-06-05T15:06-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1080A@1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-14T08:32 ADAY 9 ADOSE 12020-06-05T15:06-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1080AP1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-14T19:59 ADAY 10 ADOSE 12020-06-05T15:06-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1080A`1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-14T21:35 ADAY 10 ADOSE 12020-06-05T15:06-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1080Ap1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-15T21:35 ADAY 11 ADOSE 12020-06-05T15:06-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1080A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-15T23:42 ADAY 11 ADOSE 12020-06-05T15:06-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1080A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-16T21:35 ADAY 12 ADOSE 12020-06-05T15:06-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1080A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-17T07:38 ADAY 12 ADOSE 12020-06-05T15:06-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1080A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-17T21:35 ADAY 13 ADOSE 12020-06-05T15:06-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1080A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-18T08:32 ADAY 13 ADOSE 12020-06-05T15:06-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1080A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-18T08:32 ADAY 14 ADOSE 12020-06-05T15:06-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1084A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-12T18:13 ADAY 8 ADOSE 12020-06-05T16:20-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1090A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T15:52 B+DAY 9 ADOSE 22020-07-06T09:21-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1090A 2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-07-06T09:21-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1096A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-10T22:04 ADAY 8 ADOSE 12020-06-03T14:16-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1096A 2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 3/SEVERE GRADE 3/SEVERE . INVESTIGATOR .BLINDED TREATMENT 2020-07-09 B%DAY 8 ADOSE 22020-07-02T13:53-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1096A02080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-09T22:00 B%DAY 8 ADOSE 22020-07-02T13:53-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1096A@2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 3/SEVERE GRADE 3/SEVERE . INVESTIGATOR .BLINDED TREATMENT 2020-07-10 B&DAY 9 ADOSE 22020-07-02T13:53-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1096AP2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-10T22:01 B&DAY 9 ADOSE 22020-07-02T13:53-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1115A2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITENONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-07T19:04 B+DAY 8 ADOSE 22020-07-31T11:50-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1144A1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-12T16:25 ADAY 8 ADOSE 12020-06-05T11:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1144A 1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-12T20:12 ADAY 8 ADOSE 12020-06-05T11:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1144A01100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-13T20:12 ADAY 9 ADOSE 12020-06-05T11:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1144A@1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-14T07:12 ADAY 9 ADOSE 12020-06-05T11:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1144AP1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-14T07:12 ADAY 10 ADOSE 12020-06-05T11:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1144A`1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-12T16:25 ADAY 8 ADOSE 12020-06-05T11:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1144Ap1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-12T20:12 ADAY 8 ADOSE 12020-06-05T11:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1144A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-13T20:12 ADAY 9 ADOSE 12020-06-05T11:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1144A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-14T07:12 ADAY 9 ADOSE 12020-06-05T11:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1144A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-14T07:48 ADAY 10 ADOSE 12020-06-05T11:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1144A1090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-12 ADAY 8 ADOSE 12020-06-05T11:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1144A1090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-12T16:25 ADAY 8 ADOSE 12020-06-05T11:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1144A1090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-13 ADAY 9 ADOSE 12020-06-05T11:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1144A1090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-14 ADAY 10 ADOSE 12020-06-05T11:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1144A1090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-14T07:12 ADAY 9 ADOSE 12020-06-05T11:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1154A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-15T13:43 B)DAY 8 ADOSE 22020-07-08T14:50-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1154A 2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 3/SEVERE GRADE 3/SEVERE . INVESTIGATOR .BLINDED TREATMENT 2020-07-15T20:56 B)DAY 8 ADOSE 22020-07-08T14:50-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1154A02070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 3/SEVERE GRADE 3/SEVERE . INVESTIGATOR .BLINDED TREATMENT 2020-07-16T12:00 B*DAY 9 ADOSE 22020-07-08T14:50-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1154A@2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-16T23:59 B*DAY 9 ADOSE 22020-07-08T14:50-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1164A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-15T18:18 B&DAY 8 ADOSE 22020-07-08T10:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1164A 1030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-15 ADAY 8 ADOSE 12020-06-08T09:13-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1164A01030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-16 ADAY 9 ADOSE 12020-06-08T09:13-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1164A@1030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-17 ADAY 10 ADOSE 12020-06-08T09:13-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1164AP1030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-18 ADAY 11 ADOSE 12020-06-08T09:13-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1164A`1060SEV Severity/Intensity Underarm Gland Swelling or Tenderness REACTOGENICITY ADMINISTRATION SITEDOES NOT INTERFERE WITH ACTIVITY DOES NOT INTERFERE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-15T18:00 ADAY 8 ADOSE 12020-06-08T09:13-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1164Ap1060SEV Severity/Intensity Underarm Gland Swelling or Tenderness REACTOGENICITY ADMINISTRATION SITEDOES NOT INTERFERE WITH ACTIVITY DOES NOT INTERFERE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-16T22:04 ADAY 9 ADOSE 12020-06-08T09:13-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1164A1060SEV Severity/Intensity Underarm Gland Swelling or Tenderness REACTOGENICITY ADMINISTRATION SITEDOES NOT INTERFERE WITH ACTIVITY DOES NOT INTERFERE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-17T18:29 ADAY 10 ADOSE 12020-06-08T09:13-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1164A1060SEV Severity/Intensity Underarm Gland Swelling or Tenderness REACTOGENICITY ADMINISTRATION SITENONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-18T18:20 ADAY 11 ADOSE 12020-06-08T09:13-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1175A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 3/SEVERE GRADE 3/SEVERE . INVESTIGATOR .BLINDED TREATMENT 2020-07-15T21:31 B&DAY 8 ADOSE 22020-07-08T12:21-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1175A 2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-16T08:10 B'DAY 8 ADOSE 22020-07-08T12:21-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1175A02080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 3/SEVERE GRADE 3/SEVERE . INVESTIGATOR .BLINDED TREATMENT 2020-07-16T21:31 B'DAY 9 ADOSE 22020-07-08T12:21-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1175A@2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 3/SEVERE GRADE 3/SEVERE . INVESTIGATOR .BLINDED TREATMENT 2020-07-17T14:13 B(DAY 10 ADOSE 22020-07-08T12:21-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1175AP2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-17T14:13 B(DAY 10 ADOSE 22020-07-08T12:21-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1175A`2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-08T12:21-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1179A1130OCCUR Occurrence Indicator Rash REACTOGENICITY SYSTEMIC Y Y . STUDY SUBJECT.BLINDED TREATMENT 2020-06-15T20:35 ADAY 8 ADOSE 12020-06-08T15:12-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1179A 1130OCCUR Occurrence Indicator Rash REACTOGENICITY SYSTEMIC Y Y . STUDY SUBJECT.BLINDED TREATMENT 2020-06-16T16:52 ADAY 9 ADOSE 12020-06-08T15:12-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1179A01130OCCUR Occurrence Indicator Rash REACTOGENICITY SYSTEMIC N N . STUDY SUBJECT.BLINDED TREATMENT 2020-06-17T22:12 ADAY 10 ADOSE 12020-06-08T15:12-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180A2050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE2 mm2 A mm STUDY SUBJECT.BLINDED TREATMENT 2020-07-15T20:32 B&DAY 8 ADOSE 22020-07-08T09:58-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180A 2050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE2 mm2 A mm STUDY SUBJECT.BLINDED TREATMENT 2020-07-16T22:14 B'DAY 9 ADOSE 22020-07-08T09:58-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180A02040OCCUR Occurrence Indicator Erythema REACTOGENICITY ADMINISTRATION SITEN N . STUDY SUBJECT.BLINDED TREATMENT 2020-07-15T20:32 B&DAY 8 ADOSE 22020-07-08T09:58-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180A@1050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEN N . STUDY SUBJECT.BLINDED TREATMENT 2020-06-15T20:01 ADAY 8 ADOSE 12020-06-08T17:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180AP2050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-15T20:32 B&DAY 8 ADOSE 22020-07-08T09:58-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180A`2050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-16T22:14 B'DAY 9 ADOSE 22020-07-08T09:58-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180Ap2050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITE . NOT DONE . .DAY 10 ADOSE 22020-07-08T09:58-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180A2050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITE . NOT DONE . .DAY 11 ADOSE 22020-07-08T09:58-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180A1050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-15 ADAY 8 ADOSE 12020-06-08T17:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180A1050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-16 ADAY 9 ADOSE 12020-06-08T17:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180A1050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-17 ADAY 10 ADOSE 12020-06-08T17:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180A1050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-18 ADAY 11 ADOSE 12020-06-08T17:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180A1050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-19 ADAY 12 ADOSE 12020-06-08T17:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180A1050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-20 ADAY 13 ADOSE 12020-06-08T17:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180A1050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-21 ADAY 14 ADOSE 12020-06-08T17:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180B1050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-22 ADAY 15 ADOSE 12020-06-08T17:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180B1050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-23 BDAY 16 BDOSE 12020-06-08T17:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180B1050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-24 BDAY 17 BDOSE 12020-06-08T17:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180B1050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-25 BDAY 18 BDOSE 12020-06-08T17:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180B1050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-26 BDAY 19 BDOSE 12020-06-08T17:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180B1050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-27 BDAY 20 BDOSE 12020-06-08T17:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180B1050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-28 BDAY 21 BDOSE 12020-06-08T17:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180B1050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-29 BDAY 22 BDOSE 12020-06-08T17:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180B1050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-30 BDAY 23 BDOSE 12020-06-08T17:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180B1050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-01 BDAY 24 BDOSE 12020-06-08T17:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180B2050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-15T21:00 B&DAY 8 ADOSE 22020-07-08T09:58-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180B2050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-16T21:00 B'DAY 9 ADOSE 22020-07-08T09:58-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1180B2050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-17T09:00 B(DAY 10 ADOSE 22020-07-08T09:58-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1206A1110SEV Severity/Intensity Nausea/Vomiting REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-09T18:11 ADAY 8 ADOSE 12020-07-02T12:16-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1207A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-14T01:21 B2DAY 8 ADOSE 22020-08-06T11:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1207A 1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-03T17:15 ADAY 8 ADOSE 12020-06-26T16:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1207A02070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-14T01:21 B2DAY 8 ADOSE 22020-08-06T11:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1207A@1090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-03T17:15 ADAY 8 ADOSE 12020-06-26T16:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1208A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T19:32 ADAY 8 ADOSE 12020-07-01T15:52-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1208A 2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-05T17:28 B$DAY 8 ADOSE 22020-07-29T16:20-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1208A02070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-05T19:04 B$DAY 8 ADOSE 22020-07-29T16:20-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1208A@2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC REPEATED USE OF OVER-THE-COUNTER PAIN RELIEVER > 24 HOURS OR SOME INTERFERERENCE WITH ACTIVITY REPEATED USE OF OVER-THE-COUNTER PAIN RELIEVER > 24 HOURS OR SOME INTERFERERENCE WITH ACTIVITY. STUDY SUBJECT.BLINDED TREATMENT 2020-08-06T14:25 B%DAY 9 ADOSE 22020-07-29T16:20-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1208AP2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-06T17:28 B%DAY 9 ADOSE 22020-07-29T16:20-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1208A`2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-07T14:22 B&DAY 10 ADOSE 22020-07-29T16:20-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1208Ap2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-07T17:28 B&DAY 10 ADOSE 22020-07-29T16:20-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1208A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-08T12:03 B'DAY 11 ADOSE 22020-07-29T16:20-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1208A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-08T17:28 B'DAY 11 ADOSE 22020-07-29T16:20-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1208A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-09T13:55 B(DAY 12 ADOSE 22020-07-29T16:20-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1208A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-09T13:55 B(DAY 12 ADOSE 22020-07-29T16:20-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1217A1130OCCUR Occurrence Indicator Rash REACTOGENICITY SYSTEMIC Y Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-06T21:33 ADAY 8 ADOSE 12020-06-29T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1217A 1130OCCUR Occurrence Indicator Rash REACTOGENICITY SYSTEMIC N N . STUDY SUBJECT.BLINDED TREATMENT 2020-07-07T21:25 ADAY 9 ADOSE 12020-06-29T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1217A02080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 3/SEVERE GRADE 3/SEVERE . INVESTIGATOR .BLINDED TREATMENT 2020-08-05T16:23 B&DAY 8 ADOSE 22020-07-29T13:15-P1DmRNA-1273-P201FAmRNA-1273-P201-US202-1217A@2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-05T19:57 B&DAY 8 ADOSE 22020-07-29T13:15-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1004A2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEGRADE 3/SEVERE GRADE 3/SEVERE . INVESTIGATOR .BLINDED TREATMENT 2020-07-06T18:00 B'DAY 8 ADOSE 22020-06-29T09:40-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1004A 2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEGRADE 3/SEVERE GRADE 3/SEVERE . INVESTIGATOR .BLINDED TREATMENT 2020-07-07T10:00 B(DAY 9 ADOSE 22020-06-29T09:40-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1009A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-07-01T12:12-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1009A 2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-01T12:12-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1009A02080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-07-01T12:12-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1009A@2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-01T12:12-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1009AP2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-07-01T12:12-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1009A`2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-01T12:12-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1009Ap2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-07-01T12:12-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1009A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-01T12:12-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1011A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-09T06:43 B*DAY 8 ADOSE 22020-07-01T11:44-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1011A 2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-09T06:43 B*DAY 8 ADOSE 22020-07-01T11:44-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1035A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-06T13:29 B$DAY 8 ADOSE 22020-06-29T10:42-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1035A 2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITENONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-06T13:29 B$DAY 8 ADOSE 22020-06-29T10:42-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1042A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-13T12:02 B(DAY 8 ADOSE 22020-07-06T14:34-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1042A 2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T14:39 B)DAY 9 ADOSE 22020-07-06T14:34-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1042A02090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-13T12:01 B(DAY 8 ADOSE 22020-07-06T14:34-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1042A@2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-13T13:27 B(DAY 8 ADOSE 22020-07-06T14:34-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1042AP2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-14T13:27 B)DAY 9 ADOSE 22020-07-06T14:34-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1042A`2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T14:39 B)DAY 9 ADOSE 22020-07-06T14:34-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1042Ap2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-15T12:29 B*DAY 10 ADOSE 22020-07-06T14:34-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1042A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-15T13:27 B*DAY 10 ADOSE 22020-07-06T14:34-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1042A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-16T13:27 B+DAY 11 ADOSE 22020-07-06T14:34-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1042A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-16T13:59 B+DAY 11 ADOSE 22020-07-06T14:34-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1042A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-17T12:00 B,DAY 12 ADOSE 22020-07-06T14:34-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1042A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-17T22:56 B,DAY 12 ADOSE 22020-07-06T14:34-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1042A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-18T22:56 B-DAY 13 ADOSE 22020-07-06T14:34-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1063A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-07-02T16:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1063A 2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-02T16:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1072A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-10T19:08 ADAY 8 ADOSE 12020-06-03T12:40-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1073A1060SEV Severity/Intensity Underarm Gland Swelling or Tenderness REACTOGENICITY ADMINISTRATION SITENONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-09T21:58 ADAY 8 ADOSE 12020-06-02T11:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1074A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-07T16:19 B$DAY 8 ADOSE 22020-06-30T15:23-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1074A 2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-07T22:00 B$DAY 8 ADOSE 22020-06-30T15:23-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1074A02070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T14:37 B%DAY 9 ADOSE 22020-06-30T15:23-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1074A@2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-08T18:00 B%DAY 9 ADOSE 22020-06-30T15:23-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1074AP2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-09T21:12 B&DAY 10 ADOSE 22020-06-30T15:23-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1074A`2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-11T09:35 B(DAY 11 ADOSE 22020-06-30T15:23-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1091A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 3/SEVERE GRADE 3/SEVERE . INVESTIGATOR .BLINDED TREATMENT 2020-08-03T08:00 B'DAY 8 ADOSE 22020-07-27T10:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1091A 2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-04T07:15 B(DAY 8 ADOSE 22020-07-27T10:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1105A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-03 ADAY 8 ADOSE 12020-06-26T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1105A 1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-03T16:32 ADAY 8 ADOSE 12020-06-26T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1105A01080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-04 ADAY 9 ADOSE 12020-06-26T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1105A@1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-04T14:14 ADAY 9 ADOSE 12020-06-26T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1105AP1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-05 ADAY 10 ADOSE 12020-06-26T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1105A`1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-05T22:20 ADAY 10 ADOSE 12020-06-26T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1105Ap1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-06 ADAY 11 ADOSE 12020-06-26T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1105A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-06T16:14 ADAY 11 ADOSE 12020-06-26T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1105A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-07 ADAY 12 ADOSE 12020-06-26T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1105A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-08 ADAY 13 ADOSE 12020-06-26T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1105A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T19:00 ADAY 13 ADOSE 12020-06-26T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1105A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-09 ADAY 14 ADOSE 12020-06-26T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1105A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-09T20:23 ADAY 14 ADOSE 12020-06-26T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1105A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-12T07:17 BDAY 16 BDOSE 12020-06-26T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1105A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 12 ADOSE 12020-06-26T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US203-1105B1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 15 ADOSE 12020-06-26T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1003A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-06-30T15:37-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1003A 2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-06-30T15:37-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1003A02070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-06-30T15:37-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1003A@2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-06-30T15:37-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1006A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-09T19:26 B&DAY 8 ADOSE 22020-07-02T10:53-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1008A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-08 B&DAY 8 ADOSE 22020-07-01T15:55-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1008A 2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T19:56 B&DAY 8 ADOSE 22020-07-01T15:55-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1008A02080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-09 B'DAY 9 ADOSE 22020-07-01T15:55-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1008A@2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-10 B(DAY 10 ADOSE 22020-07-01T15:55-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1008AP2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-10T07:52 B(DAY 9 ADOSE 22020-07-01T15:55-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1008A`2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T19:56 B&DAY 8 ADOSE 22020-07-01T15:55-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1012A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-09T22:31 ADAY 8 ADOSE 12020-06-02T08:44-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1024A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-07-02T08:51-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1024A 2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-02T08:51-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1024A02070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-07-02T08:51-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1024A@2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-02T08:51-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1026A1120SEV Severity/Intensity Chills REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-09T16:27 ADAY 8 ADOSE 12020-06-02T09:55-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1026A 1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-09T16:27 ADAY 8 ADOSE 12020-06-02T09:55-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1026A01070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-09T16:27 ADAY 8 ADOSE 12020-06-02T09:55-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1055A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 12020-06-03T11:01-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1055A 1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 12020-06-03T11:01-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1060A1050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE3 mm3 A0mm STUDY SUBJECT.BLINDED TREATMENT 2020-06-09T12:00 ADAY 8 ADOSE 12020-06-02T09:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1060A 1050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-06-09T12:00 ADAY 8 ADOSE 12020-06-02T09:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1060A01050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEN N . STUDY SUBJECT.BLINDED TREATMENT 2020-06-10T12:02 ADAY 9 ADOSE 12020-06-02T09:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1060A@1030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITENONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-09T12:00 ADAY 8 ADOSE 12020-06-02T09:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1060AP2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITENONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T12:24 B%DAY 8 ADOSE 22020-07-01T09:27-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1060A`1050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-09 ADAY 8 ADOSE 12020-06-02T09:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1073A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-09T09:38 ADAY 8 ADOSE 12020-06-02T17:30-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1073A 1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-09T16:53 ADAY 8 ADOSE 12020-06-02T17:30-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1073A01080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-10T09:38 ADAY 9 ADOSE 12020-06-02T17:30-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1073A@1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-10T18:31 ADAY 9 ADOSE 12020-06-02T17:30-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1073AP1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-11T09:38 ADAY 10 ADOSE 12020-06-02T17:30-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1073A`1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-11T12:17 ADAY 10 ADOSE 12020-06-02T17:30-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1073Ap1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-12T12:38 ADAY 11 ADOSE 12020-06-02T17:30-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1073A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-12T13:29 ADAY 11 ADOSE 12020-06-02T17:30-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1073A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-14T06:04 ADAY 12 ADOSE 12020-06-02T17:30-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1073A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-07 B$DAY 8 ADOSE 22020-06-30T16:35-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1073A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-07T16:05 B$DAY 8 ADOSE 22020-06-30T16:35-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1073A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-08 B%DAY 9 ADOSE 22020-06-30T16:35-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1073A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T16:14 B%DAY 9 ADOSE 22020-06-30T16:35-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1073A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-09 B&DAY 10 ADOSE 22020-06-30T16:35-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1073A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-09T21:00 B&DAY 10 ADOSE 22020-06-30T16:35-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1073B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-10 B'DAY 11 ADOSE 22020-06-30T16:35-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1073B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-10T12:12 B'DAY 11 ADOSE 22020-06-30T16:35-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1073B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-11 B(DAY 12 ADOSE 22020-06-30T16:35-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1073B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-11T12:38 B(DAY 12 ADOSE 22020-06-30T16:35-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-09T17:00 ADAY 8 ADOSE 12020-06-02T11:57-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076A 1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-09T17:43 ADAY 8 ADOSE 12020-06-02T11:57-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076A01080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-10T17:00 ADAY 9 ADOSE 12020-06-02T11:57-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076A@1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-10T22:29 ADAY 9 ADOSE 12020-06-02T11:57-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076AP1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-11T17:12 ADAY 10 ADOSE 12020-06-02T11:57-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076A`1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-11T22:00 ADAY 10 ADOSE 12020-06-02T11:57-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076Ap1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-12T13:06 ADAY 11 ADOSE 12020-06-02T11:57-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-13T21:54 B*DAY 8 ADOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T18:06 B+DAY 9 ADOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-15T17:21 B,DAY 10 ADOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-16T18:03 B-DAY 11 ADOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-17T18:12 B.DAY 12 ADOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-18T12:50 B/DAY 13 ADOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-19T17:11 B0DAY 14 ADOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-21T20:03 B2DAY 16 BDOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-22T20:37 B3DAY 17 BDOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-23T18:08 B4DAY 18 BDOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-24T15:16 B5DAY 19 BDOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-25T14:35 B6DAY 20 BDOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 15 ADOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 21 BDOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 22 BDOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-09 ADAY 8 ADOSE 12020-06-02T11:57-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC REPEATED USE OF OVER-THE-COUNTER PAIN RELIEVER > 24 HOURS OR SOME INTERFERERENCE WITH ACTIVITY REPEATED USE OF OVER-THE-COUNTER PAIN RELIEVER > 24 HOURS OR SOME INTERFERERENCE WITH ACTIVITY. STUDY SUBJECT.BLINDED TREATMENT 2020-06-09T17:42 ADAY 8 ADOSE 12020-06-02T11:57-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-10 ADAY 9 ADOSE 12020-06-02T11:57-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-10T22:29 ADAY 9 ADOSE 12020-06-02T11:57-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-11 ADAY 10 ADOSE 12020-06-02T11:57-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC REPEATED USE OF OVER-THE-COUNTER PAIN RELIEVER > 24 HOURS OR SOME INTERFERERENCE WITH ACTIVITY REPEATED USE OF OVER-THE-COUNTER PAIN RELIEVER > 24 HOURS OR SOME INTERFERERENCE WITH ACTIVITY. STUDY SUBJECT.BLINDED TREATMENT 2020-06-11T17:12 ADAY 10 ADOSE 12020-06-02T11:57-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-12 ADAY 11 ADOSE 12020-06-02T11:57-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-12T13:06 ADAY 11 ADOSE 12020-06-02T11:57-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-13T13:30 B*DAY 8 ADOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B 2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-13T21:54 B*DAY 8 ADOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B!2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-14T13:30 B+DAY 9 ADOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B"2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T18:06 B+DAY 9 ADOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B#2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-15 B,DAY 10 ADOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B$2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-15T17:21 B,DAY 10 ADOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B%2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-13T13:30 B*DAY 8 ADOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B&2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-13T21:54 B*DAY 8 ADOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B'2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-14T13:30 B+DAY 9 ADOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1076B(2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T18:06 B+DAY 9 ADOSE 22020-07-06T12:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1094A2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITENONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-01T08:42 B%DAY 8 ADOSE 22020-07-24T14:10-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1103A1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-03T20:06 ADAY 8 ADOSE 12020-06-26T11:33-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1103A 2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-07-24T11:46-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1103A02100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-24T11:46-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1104A1030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITENONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-03T20:10 ADAY 8 ADOSE 12020-06-26T11:47-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1107A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-04T10:33 B(DAY 8 ADOSE 22020-07-27T11:12-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1115A1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T20:28 ADAY 8 ADOSE 12020-07-01T13:21-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1115A 1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T20:27 ADAY 8 ADOSE 12020-07-01T13:21-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1115A01090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T20:28 ADAY 8 ADOSE 12020-07-01T13:21-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1120A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 12020-06-30T14:26-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1120A 1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 12020-06-30T14:26-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1120A01090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 12020-06-30T14:26-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1120A@1090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 12020-06-30T14:26-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1122A2050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITE . NOT DONE . .DAY 8 ADOSE 22020-07-27T14:07-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1122A 2050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITE . NOT DONE . .DAY 9 ADOSE 22020-07-27T14:07-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1126A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-03 ADAY 8 ADOSE 12020-06-26T12:45-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1126A 1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-03T19:25 ADAY 8 ADOSE 12020-06-26T12:45-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1126A01070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-04 ADAY 9 ADOSE 12020-06-26T12:45-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1126A@1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-04T17:24 ADAY 9 ADOSE 12020-06-26T12:45-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1145A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-08T08:15 B&DAY 8 ADOSE 22020-07-31T09:20-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1155A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-10T13:09 B$DAY 8 ADOSE 22020-08-03T14:15-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1155A 2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-10T18:13 B$DAY 8 ADOSE 22020-08-03T14:15-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1155A02070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-11T12:16 B%DAY 9 ADOSE 22020-08-03T14:15-P1DmRNA-1273-P201FAmRNA-1273-P201-US204-1155A@2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-11T13:09 B%DAY 9 ADOSE 22020-08-03T14:15-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1009A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T09:36 B%DAY 8 ADOSE 22020-06-30T08:58-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1019A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-16T21:55 ADAY 8 ADOSE 12020-06-09T10:53-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1019A 1110SEV Severity/Intensity Nausea/Vomiting REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-16T21:56 ADAY 8 ADOSE 12020-06-09T10:53-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1031A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 12020-06-02T15:35-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1031A 1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 12020-06-02T15:35-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1031A01070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 12020-06-02T15:35-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1031A@1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 12020-06-02T15:35-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1033A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 3/SEVERE GRADE 3/SEVERE . INVESTIGATOR .BLINDED TREATMENT 2020-07-14 B)DAY 8 ADOSE 22020-07-07T10:16-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1033A 2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 3/SEVERE GRADE 3/SEVERE . INVESTIGATOR .BLINDED TREATMENT 2020-07-15 B*DAY 9 ADOSE 22020-07-07T10:16-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1033A02080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-14 B)DAY 8 ADOSE 22020-07-07T10:16-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1033A@2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T19:04 B)DAY 8 ADOSE 22020-07-07T10:16-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1033AP2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-15 B*DAY 9 ADOSE 22020-07-07T10:16-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1033A`2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-15T16:36 B*DAY 9 ADOSE 22020-07-07T10:16-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1033Ap2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-16T12:00 B+DAY 10 ADOSE 22020-07-07T10:16-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057A1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-03 ADAY 8 ADOSE 12020-06-26T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057A 1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-03T14:13 ADAY 8 ADOSE 12020-06-26T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057A01100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-04 ADAY 9 ADOSE 12020-06-26T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057A@1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-04T12:25 ADAY 9 ADOSE 12020-06-26T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057AP1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-05 ADAY 10 ADOSE 12020-06-26T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057A`1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-06 ADAY 11 ADOSE 12020-06-26T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057Ap1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-06T06:09 ADAY 10 ADOSE 12020-06-26T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057A1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-06T12:01 ADAY 11 ADOSE 12020-06-26T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-03 ADAY 8 ADOSE 12020-06-26T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-03T14:13 ADAY 8 ADOSE 12020-06-26T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-04 ADAY 9 ADOSE 12020-06-26T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-04T12:24 ADAY 9 ADOSE 12020-06-26T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-05 ADAY 10 ADOSE 12020-06-26T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-06 ADAY 11 ADOSE 12020-06-26T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-06T06:09 ADAY 10 ADOSE 12020-06-26T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-06T12:01 ADAY 11 ADOSE 12020-06-26T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-07 ADAY 12 ADOSE 12020-06-26T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-07T12:30 ADAY 12 ADOSE 12020-06-26T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-08 ADAY 13 ADOSE 12020-06-26T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T12:04 ADAY 13 ADOSE 12020-06-26T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-31 B$DAY 8 ADOSE 22020-07-24T09:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-31T12:10 B$DAY 8 ADOSE 22020-07-24T09:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-02T14:25 B&DAY 10 ADOSE 22020-07-24T09:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-24T09:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-31T12:10 B$DAY 8 ADOSE 22020-07-24T09:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-31 B$DAY 8 ADOSE 22020-07-24T09:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-31T12:10 B$DAY 8 ADOSE 22020-07-24T09:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-02T14:25 B&DAY 10 ADOSE 22020-07-24T09:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-24T09:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEGRADE 2/MODERATE GRADE 2/MODERATE . INVESTIGATOR .BLINDED TREATMENT 2020-07-31T10:00 B$DAY 8 ADOSE 22020-07-24T09:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEDOES NOT INTERFERE WITH ACTIVITY DOES NOT INTERFERE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-31T12:10 B$DAY 8 ADOSE 22020-07-24T09:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B 2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEGRADE 2/MODERATE GRADE 2/MODERATE . INVESTIGATOR .BLINDED TREATMENT 2020-08-01T10:00 B%DAY 9 ADOSE 22020-07-24T09:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B!2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEGRADE 2/MODERATE GRADE 2/MODERATE . INVESTIGATOR .BLINDED TREATMENT 2020-08-02T10:00 B&DAY 10 ADOSE 22020-07-24T09:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B"2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEDOES NOT INTERFERE WITH ACTIVITY DOES NOT INTERFERE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-02T14:25 B&DAY 10 ADOSE 22020-07-24T09:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B#2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEGRADE 2/MODERATE GRADE 2/MODERATE . INVESTIGATOR .BLINDED TREATMENT 2020-08-03T10:00 B'DAY 11 ADOSE 22020-07-24T09:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B$2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEDOES NOT INTERFERE WITH ACTIVITY DOES NOT INTERFERE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-03T16:50 B'DAY 11 ADOSE 22020-07-24T09:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B%2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEGRADE 2/MODERATE GRADE 2/MODERATE . INVESTIGATOR .BLINDED TREATMENT 2020-08-04T10:00 B(DAY 12 ADOSE 22020-07-24T09:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B&2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEDOES NOT INTERFERE WITH ACTIVITY DOES NOT INTERFERE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-04T12:12 B(DAY 12 ADOSE 22020-07-24T09:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B'2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEGRADE 2/MODERATE GRADE 2/MODERATE . INVESTIGATOR .BLINDED TREATMENT 2020-08-05T00:00 B)DAY 13 ADOSE 22020-07-24T09:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B(2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITENONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-05T12:03 B)DAY 13 ADOSE 22020-07-24T09:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B)2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITE . NOT DONE . .DAY 9 ADOSE 22020-07-24T09:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1057B*2060SEV Severity/Intensity Underarm Gland Swelling or Tenderness REACTOGENICITY ADMINISTRATION SITENONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-31T12:11 B$DAY 8 ADOSE 22020-07-24T09:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1059A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-07-27T13:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1059A 2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-27T13:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1068A1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 12020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1068A 2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-04T19:06 B$DAY 8 ADOSE 22020-07-28T13:08-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1068A02100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-04T19:06 B$DAY 8 ADOSE 22020-07-28T13:08-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1068A@2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-28T13:08-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1068AP2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 10 ADOSE 22020-07-28T13:08-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1068A`1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 12020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1068Ap2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-04T19:05 B$DAY 8 ADOSE 22020-07-28T13:08-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1068A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-04T19:05 B$DAY 8 ADOSE 22020-07-28T13:08-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1068A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-28T13:08-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1068A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 10 ADOSE 22020-07-28T13:08-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1068A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-04T19:06 B$DAY 8 ADOSE 22020-07-28T13:08-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1068A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-04T19:06 B$DAY 8 ADOSE 22020-07-28T13:08-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1068A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-28T13:08-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1068A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 10 ADOSE 22020-07-28T13:08-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1069A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-03T00:00 ADAY 8 ADOSE 12020-06-26T13:49-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1069A 1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-03T22:08 ADAY 8 ADOSE 12020-06-26T13:49-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1069A01080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-04T15:28 ADAY 9 ADOSE 12020-06-26T13:49-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1071A2130OCCUR Occurrence Indicator Rash REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-07-27T14:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1071A 2130OCCUR Occurrence Indicator Rash REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-27T14:29-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1081A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-06T21:55 ADAY 8 ADOSE 12020-06-29T12:49-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1088A1130OCCUR Occurrence Indicator Rash REACTOGENICITY SYSTEMIC N N . STUDY SUBJECT.BLINDED TREATMENT 2020-07-07T21:27 ADAY 8 ADOSE 12020-06-30T13:28-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1089A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 12020-07-02T12:33-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1089A 1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 12020-07-02T12:33-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1089A01070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 12020-07-02T12:33-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1089A@1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 12020-07-02T12:33-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1089AP1110SEV Severity/Intensity Nausea/Vomiting REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 12020-07-02T12:33-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1089A`1110SEV Severity/Intensity Nausea/Vomiting REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 12020-07-02T12:33-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1101A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-08-10T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1101A 2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-08-10T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1101A02120SEV Severity/Intensity Chills REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-08-10T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1101A@2120SEV Severity/Intensity Chills REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-08-10T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1101AP2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-08-10T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1101A`2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-08-10T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1101Ap2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-08-10T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1101A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-08-10T09:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1103A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-09T20:45 ADAY 8 ADOSE 12020-07-02T15:41-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1105A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-07-31T10:27-P1DmRNA-1273-P201FAmRNA-1273-P201-US205-1105A 2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-31T10:27-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-13T20:00 B)DAY 8 ADOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008A 2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-13T22:11 B)DAY 8 ADOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008A02100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-14T20:00 B*DAY 9 ADOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008A@2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T23:26 B*DAY 9 ADOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008AP2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-15T20:00 B+DAY 10 ADOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008A`2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-15T22:37 B+DAY 10 ADOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008Ap2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-16T20:00 B,DAY 11 ADOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-17T06:00 B-DAY 11 ADOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-17T20:00 B-DAY 12 ADOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-18T10:15 B.DAY 12 ADOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-18T20:00 B.DAY 13 ADOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-19T09:53 B/DAY 13 ADOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-19T20:00 B/DAY 14 ADOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-19T22:27 B/DAY 14 ADOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-20T20:00 B0DAY 15 ADOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-20T22:17 B0DAY 15 ADOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-21T20:00 B1DAY 16 BDOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-21T22:07 B1DAY 16 BDOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-22T20:00 B2DAY 17 BDOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-23T07:53 B3DAY 17 BDOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-23T20:00 B3DAY 18 BDOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-23T22:20 B3DAY 18 BDOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-24T20:00 B4DAY 19 BDOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-25T08:07 B5DAY 19 BDOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-25T20:00 B5DAY 20 BDOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-25T22:56 B5DAY 20 BDOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-26T20:00 B6DAY 21 BDOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-26T22:09 B6DAY 21 BDOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-27T20:00 B7DAY 22 BDOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-28T09:03 B8DAY 22 BDOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-28T20:00 B8DAY 23 BDOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B 2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-28T21:29 B8DAY 23 BDOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B!2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-29T20:00 B9DAY 24 BDOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B"2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-29T22:52 B9DAY 24 BDOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B#2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-31T08:04 B;DAY 25 BDOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B$2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-13T06:00 B)DAY 8 ADOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B%2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-13T22:12 B)DAY 8 ADOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B&2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-14T07:00 B*DAY 9 ADOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1008B'2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T23:26 B*DAY 9 ADOSE 22020-07-06T09:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1015A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-10 ADAY 8 ADOSE 12020-06-03T14:57-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1015A 1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-10T21:01 ADAY 8 ADOSE 12020-06-03T14:57-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1015A01080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 12020-06-03T14:57-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1015A@1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 10 ADOSE 12020-06-03T14:57-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1015AP1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC ANY USE OF PRESCRIPTION PAIN RELIEVER OR PREVENTS DAILY ACTIVITY ANY USE OF PRESCRIPTION PAIN RELIEVER OR PREVENTS DAILY ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-10T21:01 ADAY 8 ADOSE 12020-06-03T14:57-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1015A`1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 12020-06-03T14:57-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1015Ap1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 10 ADOSE 12020-06-03T14:57-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1019A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T13:29 B$DAY 8 ADOSE 22020-07-01T14:25-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1023A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-13 B'DAY 8 ADOSE 22020-07-06T09:40-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1023A 2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-14 B(DAY 9 ADOSE 22020-07-06T09:40-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1023A02090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T07:42 B(DAY 8 ADOSE 22020-07-06T09:40-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1023A@2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T18:43 B(DAY 9 ADOSE 22020-07-06T09:40-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1023AP2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-15 B)DAY 10 ADOSE 22020-07-06T09:40-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1023A`2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-16 B*DAY 11 ADOSE 22020-07-06T09:40-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1023Ap2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-16T08:24 B*DAY 10 ADOSE 22020-07-06T09:40-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1023A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-17 B+DAY 12 ADOSE 22020-07-06T09:40-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1023A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-17T03:34 B+DAY 11 ADOSE 22020-07-06T09:40-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1023A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-17T23:59 B+DAY 12 ADOSE 22020-07-06T09:40-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1023A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-18 B,DAY 13 ADOSE 22020-07-06T09:40-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1023A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-18T20:30 B,DAY 13 ADOSE 22020-07-06T09:40-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1023A1030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-12 ADAY 8 ADOSE 12020-06-05T11:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1023A1060SEV Severity/Intensity Underarm Gland Swelling or Tenderness REACTOGENICITY ADMINISTRATION SITEDOES NOT INTERFERE WITH ACTIVITY DOES NOT INTERFERE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-12T16:50 ADAY 8 ADOSE 12020-06-05T11:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1023A1060SEV Severity/Intensity Underarm Gland Swelling or Tenderness REACTOGENICITY ADMINISTRATION SITENONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-14T09:35 ADAY 9 ADOSE 12020-06-05T11:36-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1043A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-03T18:00 B$DAY 8 ADOSE 22020-07-27T14:46-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1043A 2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-03T22:28 B$DAY 8 ADOSE 22020-07-27T14:46-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1043A02100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-05T07:36 B&DAY 9 ADOSE 22020-07-27T14:46-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1043A@2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-06T00:32 B'DAY 10 ADOSE 22020-07-27T14:46-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1043AP2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-06T12:12 B'DAY 11 ADOSE 22020-07-27T14:46-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1043A`2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-03T18:00 B$DAY 8 ADOSE 22020-07-27T14:46-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1043Ap2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-03T22:28 B$DAY 8 ADOSE 22020-07-27T14:46-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1043A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-05T07:35 B&DAY 9 ADOSE 22020-07-27T14:46-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1043A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-03T18:00 B$DAY 8 ADOSE 22020-07-27T14:46-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1043A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-03T22:28 B$DAY 8 ADOSE 22020-07-27T14:46-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1043A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-05T07:36 B&DAY 9 ADOSE 22020-07-27T14:46-P1DmRNA-1273-P201FAmRNA-1273-P201-US206-1051A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-07T13:16 ADAY 8 ADOSE 12020-06-30T11:03-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1001A2110SEV Severity/Intensity Nausea/Vomiting REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-07T22:41 B(DAY 8 ADOSE 22020-06-30T13:38-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002A2050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE5 mm5 APmm STUDY SUBJECT.BLINDED TREATMENT 2020-07-07T21:32 B%DAY 8 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002A 2050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-07T21:32 B%DAY 8 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002A02050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEN N . STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T20:58 B&DAY 9 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002A@2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-07T08:00 B%DAY 8 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002AP2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-07T21:33 B%DAY 8 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002A`2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-08T08:00 B&DAY 9 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002Ap2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-07 B%DAY 8 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-07T21:32 B%DAY 8 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-08 B&DAY 9 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T20:58 B&DAY 9 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-09 B'DAY 10 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-09T20:57 B'DAY 10 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-10 B(DAY 11 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-11T00:00 B)DAY 11 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-11 B)DAY 12 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-11T21:44 B)DAY 12 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-12 B*DAY 13 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-12T21:25 B*DAY 13 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-13 B+DAY 14 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-13T20:20 B+DAY 14 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-14 B,DAY 15 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T21:31 B,DAY 15 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-15 B-DAY 16 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-15T20:13 B-DAY 16 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-16 B.DAY 17 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-16T20:47 B.DAY 17 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-17 B/DAY 18 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-17T21:31 B/DAY 18 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-18 B0DAY 19 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-18T21:05 B0DAY 19 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-19 B1DAY 20 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B 2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-19T20:37 B1DAY 20 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B!2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-20 B2DAY 21 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B"2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-20T21:40 B2DAY 21 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B#2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-21 B3DAY 22 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B$2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-22 B4DAY 23 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B%2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-22T05:18 B4DAY 22 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B&2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-22T21:38 B4DAY 23 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B'2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-23 B5DAY 24 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B(2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-23T22:57 B5DAY 24 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B)2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-24 B6DAY 25 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B*2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-24T21:49 B6DAY 25 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B+2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-25 B7DAY 26 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B,2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-25T23:59 B7DAY 26 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B-2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-26 B8DAY 27 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B.2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-26T22:58 B8DAY 27 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B/2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .PART A FOLLOW-UP 2020-07-27 B9DAY 28 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B02080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.PART A FOLLOW-UP 2020-07-27T23:59 B9DAY 28 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B12080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .PART A FOLLOW-UP 2020-07-28 B:DAY 29 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B22080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .PART A FOLLOW-UP 2020-07-29 B;DAY 30 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B32080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.PART A FOLLOW-UP 2020-07-29T00:11 B;DAY 29 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B42080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.PART A FOLLOW-UP 2020-07-29T23:59 B;DAY 30 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B52080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .PART A FOLLOW-UP 2020-07-30 B<DAY 31 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B62080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.PART A FOLLOW-UP 2020-07-30T23:27 B<DAY 31 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B72080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .PART A FOLLOW-UP 2020-07-31 B=DAY 32 B DOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B82080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .PART A FOLLOW-UP 2020-08-01 B>DAY 33 B!DOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B92080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.PART A FOLLOW-UP 2020-08-01T08:34 B>DAY 32 B DOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B:2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.PART A FOLLOW-UP 2020-08-01T20:21 B>DAY 33 B!DOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B;2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .PART A FOLLOW-UP 2020-08-02 B?DAY 34 B"DOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B<2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 34 B"DOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B=2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 35 B#DOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B>2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-07T20:00 B%DAY 8 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B?2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC REPEATED USE OF OVER-THE-COUNTER PAIN RELIEVER > 24 HOURS OR SOME INTERFERERENCE WITH ACTIVITY REPEATED USE OF OVER-THE-COUNTER PAIN RELIEVER > 24 HOURS OR SOME INTERFERERENCE WITH ACTIVITY. STUDY SUBJECT.BLINDED TREATMENT 2020-07-07T21:32 B%DAY 8 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002B@2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-08T20:00 B&DAY 9 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BA2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC REPEATED USE OF OVER-THE-COUNTER PAIN RELIEVER > 24 HOURS OR SOME INTERFERERENCE WITH ACTIVITY REPEATED USE OF OVER-THE-COUNTER PAIN RELIEVER > 24 HOURS OR SOME INTERFERERENCE WITH ACTIVITY. STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T20:58 B&DAY 9 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BB2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-09T20:00 B'DAY 10 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BC2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC REPEATED USE OF OVER-THE-COUNTER PAIN RELIEVER > 24 HOURS OR SOME INTERFERERENCE WITH ACTIVITY REPEATED USE OF OVER-THE-COUNTER PAIN RELIEVER > 24 HOURS OR SOME INTERFERERENCE WITH ACTIVITY. STUDY SUBJECT.BLINDED TREATMENT 2020-07-09T20:57 B'DAY 10 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BD2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-10T20:00 B(DAY 11 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BE2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC REPEATED USE OF OVER-THE-COUNTER PAIN RELIEVER > 24 HOURS OR SOME INTERFERERENCE WITH ACTIVITY REPEATED USE OF OVER-THE-COUNTER PAIN RELIEVER > 24 HOURS OR SOME INTERFERERENCE WITH ACTIVITY. STUDY SUBJECT.BLINDED TREATMENT 2020-07-11T00:00 B)DAY 11 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BF2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-11T20:00 B)DAY 12 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BG2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-11T21:44 B)DAY 12 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BH2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-12T08:00 B*DAY 13 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BI2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC REPEATED USE OF OVER-THE-COUNTER PAIN RELIEVER > 24 HOURS OR SOME INTERFERERENCE WITH ACTIVITY REPEATED USE OF OVER-THE-COUNTER PAIN RELIEVER > 24 HOURS OR SOME INTERFERERENCE WITH ACTIVITY. STUDY SUBJECT.BLINDED TREATMENT 2020-07-12T21:25 B*DAY 13 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BJ2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC REPEATED USE OF OVER-THE-COUNTER PAIN RELIEVER > 24 HOURS OR SOME INTERFERERENCE WITH ACTIVITY REPEATED USE OF OVER-THE-COUNTER PAIN RELIEVER > 24 HOURS OR SOME INTERFERERENCE WITH ACTIVITY. STUDY SUBJECT.BLINDED TREATMENT 2020-07-13T20:20 B+DAY 14 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BK2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T21:31 B,DAY 15 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BL2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-15T20:13 B-DAY 16 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BM2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-16T20:47 B.DAY 17 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BN2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-17T21:31 B/DAY 18 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BO2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-18T21:05 B0DAY 19 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BP2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-19T20:37 B1DAY 20 BDOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BQ2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-07T21:33 B%DAY 8 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BR2110SEV Severity/Intensity Nausea/Vomiting REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-07 B%DAY 8 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BS2110SEV Severity/Intensity Nausea/Vomiting REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY OR 1-2 EPISODES/24 HOURS NO INTERFERENCE WITH ACTIVITY OR 1-2 EPISODES/24 HOURS . STUDY SUBJECT.BLINDED TREATMENT 2020-07-07T21:33 B%DAY 8 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BT2110SEV Severity/Intensity Nausea/Vomiting REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-08 B&DAY 9 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BU2110SEV Severity/Intensity Nausea/Vomiting REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY OR 1-2 EPISODES/24 HOURS NO INTERFERENCE WITH ACTIVITY OR 1-2 EPISODES/24 HOURS . STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T20:58 B&DAY 9 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BV2110SEV Severity/Intensity Nausea/Vomiting REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-09 B'DAY 10 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BW2110SEV Severity/Intensity Nausea/Vomiting REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-09T20:57 B'DAY 10 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1002BX2050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-07 B%DAY 8 ADOSE 22020-06-30T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1003A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-06-30T13:44-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1003A 2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-06-30T13:44-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1004A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-15 B*DAY 8 ADOSE 22020-07-08T09:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1004A 2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-15T20:20 B*DAY 8 ADOSE 22020-07-08T09:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1004A02080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-16 B+DAY 9 ADOSE 22020-07-08T09:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1004A@2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-16T20:47 B+DAY 9 ADOSE 22020-07-08T09:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1004AP2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-17T21:32 B,DAY 10 ADOSE 22020-07-08T09:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1004A`2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-18T22:19 B-DAY 11 ADOSE 22020-07-08T09:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1004Ap2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-19T20:38 B.DAY 12 ADOSE 22020-07-08T09:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1004A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-20T20:47 B/DAY 13 ADOSE 22020-07-08T09:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1004A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-22T07:09 B1DAY 14 ADOSE 22020-07-08T09:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1004A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-22T19:56 B1DAY 15 ADOSE 22020-07-08T09:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1004A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-15T08:00 B*DAY 8 ADOSE 22020-07-08T09:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1004A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-15T20:19 B*DAY 8 ADOSE 22020-07-08T09:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1004A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-16 B+DAY 9 ADOSE 22020-07-08T09:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1004A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-16T20:47 B+DAY 9 ADOSE 22020-07-08T09:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1004A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-17T21:31 B,DAY 10 ADOSE 22020-07-08T09:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1004B2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-18T22:19 B-DAY 11 ADOSE 22020-07-08T09:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1004B2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-19T20:38 B.DAY 12 ADOSE 22020-07-08T09:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1004B2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-20T20:46 B/DAY 13 ADOSE 22020-07-08T09:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1004B2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-22T07:09 B1DAY 14 ADOSE 22020-07-08T09:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1004B2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-22T19:56 B1DAY 15 ADOSE 22020-07-08T09:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1004B2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-15 B*DAY 8 ADOSE 22020-07-08T09:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1004B2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-15T20:20 B*DAY 8 ADOSE 22020-07-08T09:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1022A1060SEV Severity/Intensity Underarm Gland Swelling or Tenderness REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-10 ADAY 8 ADOSE 12020-06-03T12:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1022A 1060SEV Severity/Intensity Underarm Gland Swelling or Tenderness REACTOGENICITY ADMINISTRATION SITEDOES NOT INTERFERE WITH ACTIVITY DOES NOT INTERFERE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-10T15:17 ADAY 8 ADOSE 12020-06-03T12:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1022A01060SEV Severity/Intensity Underarm Gland Swelling or Tenderness REACTOGENICITY ADMINISTRATION SITENONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-11T14:56 ADAY 9 ADOSE 12020-06-03T12:19-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1030A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-10T16:18 ADAY 8 ADOSE 12020-06-03T17:16-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1038A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-11T22:37 ADAY 8 ADOSE 12020-06-04T14:02-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1059A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-15T23:40 ADAY 8 ADOSE 12020-06-08T16:05-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1062A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-15T03:01 B*DAY 8 ADOSE 22020-07-07T14:35-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1073A1050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITE . NOT DONE . .DAY 8 ADOSE 12020-06-08T12:07-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1085A1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-03T17:31 ADAY 8 ADOSE 12020-06-26T14:43-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1085A 1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-04T22:17 ADAY 9 ADOSE 12020-06-26T14:43-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1085A01100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-05T18:04 ADAY 10 ADOSE 12020-06-26T14:43-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1085A@1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-06T18:29 ADAY 11 ADOSE 12020-06-26T14:43-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1089A1110SEV Severity/Intensity Nausea/Vomiting REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-03T12:49 ADAY 8 ADOSE 12020-06-26T09:40-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1094A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-11T22:00 B%DAY 8 ADOSE 22020-08-04T12:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1094A 2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-11T22:00 B%DAY 8 ADOSE 22020-08-04T12:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1100A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-12T05:57 B&DAY 8 ADOSE 22020-08-04T10:47-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1100A 2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-12T21:01 B&DAY 9 ADOSE 22020-08-04T10:47-P1DmRNA-1273-P201FAmRNA-1273-P201-US207-1100A02100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-14T05:17 B(DAY 10 ADOSE 22020-08-04T10:47-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1033A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-07-07T10:39-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1033A 2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-07T10:39-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1036A2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-07-09T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1036A 2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-09T13:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1039A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-17T04:33 ADAY 9 ADOSE 12020-06-08T13:44-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1039A 1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 12020-06-08T13:44-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1039A02080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-15T20:49 B&DAY 8 ADOSE 22020-07-08T12:08-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1045A2120SEV Severity/Intensity Chills REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-07-07T14:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1045A 2120SEV Severity/Intensity Chills REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-07T14:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1045A02080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-07-07T14:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1045A@2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-07T14:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1045AP2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-07-07T14:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1045A`2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-07T14:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1045Ap2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-07-07T14:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1045A2090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-07T14:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1045A2110SEV Severity/Intensity Nausea/Vomiting REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 8 ADOSE 22020-07-07T14:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1045A2110SEV Severity/Intensity Nausea/Vomiting REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 22020-07-07T14:18-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1057A1100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-12T14:03 ADAY 8 ADOSE 12020-06-05T13:45-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1057A 1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-12 ADAY 8 ADOSE 12020-06-05T13:45-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1057A01080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-12T14:03 ADAY 8 ADOSE 12020-06-05T13:45-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1057A@1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-13T22:18 ADAY 9 ADOSE 12020-06-05T13:45-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1057AP1090SEV Severity/Intensity Myalgia REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-12T14:03 ADAY 8 ADOSE 12020-06-05T13:45-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1057A`1060SEV Severity/Intensity Underarm Gland Swelling or Tenderness REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-06-12 ADAY 8 ADOSE 12020-06-05T13:45-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1057Ap1060SEV Severity/Intensity Underarm Gland Swelling or Tenderness REACTOGENICITY ADMINISTRATION SITEDOES NOT INTERFERE WITH ACTIVITY DOES NOT INTERFERE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-06-12T14:03 ADAY 8 ADOSE 12020-06-05T13:45-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1057A1060SEV Severity/Intensity Underarm Gland Swelling or Tenderness REACTOGENICITY ADMINISTRATION SITENONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-06-13T22:18 ADAY 9 ADOSE 12020-06-05T13:45-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069A1050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE5 mm5 APmm STUDY SUBJECT.BLINDED TREATMENT 2020-07-03T21:16 ADAY 8 ADOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069A 1050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE5 mm5 APmm STUDY SUBJECT.BLINDED TREATMENT 2020-07-04T15:20 ADAY 9 ADOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069A01050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE4 mm4 A@mm STUDY SUBJECT.BLINDED TREATMENT 2020-07-05T21:44 ADAY 10 ADOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069A@1050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE4 mm4 A@mm STUDY SUBJECT.BLINDED TREATMENT 2020-07-06T21:23 ADAY 11 ADOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069AP1050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE4 mm4 A@mm STUDY SUBJECT.BLINDED TREATMENT 2020-07-07T22:27 ADAY 12 ADOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069A`1050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE4 mm4 A@mm STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T13:59 ADAY 13 ADOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069Ap1050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE4 mm4 A@mm STUDY SUBJECT.BLINDED TREATMENT 2020-07-09T22:09 ADAY 14 ADOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069A1050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE4 mm4 A@mm STUDY SUBJECT.BLINDED TREATMENT 2020-07-10T21:04 ADAY 15 ADOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069A1050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE3 mm3 A0mm STUDY SUBJECT.BLINDED TREATMENT 2020-07-12T07:35 BDAY 16 BDOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069A1050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE3 mm3 A0mm STUDY SUBJECT.BLINDED TREATMENT 2020-07-12T17:39 BDAY 17 BDOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069A1050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE2 mm2 A mm STUDY SUBJECT.BLINDED TREATMENT 2020-07-13T20:43 BDAY 18 BDOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069A1050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE2 mm2 A mm STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T22:06 BDAY 19 BDOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069A1050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE2 mm2 A mm STUDY SUBJECT.BLINDED TREATMENT 2020-07-15T21:06 BDAY 20 BDOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069A1050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE2 mm2 A mm STUDY SUBJECT.BLINDED TREATMENT 2020-07-17T06:21 BDAY 21 BDOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069A1050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE2 mm2 A mm STUDY SUBJECT.BLINDED TREATMENT 2020-07-18T10:08 BDAY 22 BDOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B1050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE2 mm2 A mm STUDY SUBJECT.BLINDED TREATMENT 2020-07-18T22:45 BDAY 23 BDOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B1050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE2 mm2 A mm STUDY SUBJECT.BLINDED TREATMENT 2020-07-19T12:45 BDAY 24 BDOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B1050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE2 mm2 A mm STUDY SUBJECT.BLINDED TREATMENT 2020-07-20T15:17 BDAY 25 BDOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B1050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-03T21:16 ADAY 8 ADOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B1050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-04T15:20 ADAY 9 ADOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B1050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-05T21:44 ADAY 10 ADOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B1050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-06T21:23 ADAY 11 ADOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B1050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-07T22:27 ADAY 12 ADOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B1050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-08T13:59 ADAY 13 ADOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B1050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-09T22:09 ADAY 14 ADOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B1050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-10T21:04 ADAY 15 ADOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B1050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-12T07:35 BDAY 16 BDOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B1050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-12T17:39 BDAY 17 BDOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B1050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-13T20:43 BDAY 18 BDOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B1050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T22:06 BDAY 19 BDOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B1050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-15T21:06 BDAY 20 BDOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B 1050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-17T06:21 BDAY 21 BDOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B!1050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-18T10:08 BDAY 22 BDOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B"1050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-18T22:45 BDAY 23 BDOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B#1050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-19T12:45 BDAY 24 BDOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B$1050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-20T15:17 BDAY 25 BDOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B%1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-03 ADAY 8 ADOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B&1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-03T21:17 ADAY 8 ADOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1069B'1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-04T15:20 ADAY 9 ADOSE 12020-06-26T14:54-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1076A2050LDIAM Longest Diameter Swelling REACTOGENICITY ADMINISTRATION SITE10 mm10 Amm STUDY SUBJECT.BLINDED TREATMENT 2020-08-12T19:20 B+DAY 8 ADOSE 22020-08-05T14:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1076A 2050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEY Y . STUDY SUBJECT.BLINDED TREATMENT 2020-08-12T19:20 B+DAY 8 ADOSE 22020-08-05T14:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1076A02050OCCUR Occurrence Indicator Swelling REACTOGENICITY ADMINISTRATION SITEN N . STUDY SUBJECT.BLINDED TREATMENT 2020-08-13T18:00 B,DAY 9 ADOSE 22020-08-05T14:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1076A@2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITENONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-12T19:20 B+DAY 8 ADOSE 22020-08-05T14:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1076AP2050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-12 B+DAY 8 ADOSE 22020-08-05T14:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1076A`2050SEV Severity/Intensity Swelling REACTOGENICITY ADMINISTRATION SITEGRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-13 B,DAY 9 ADOSE 22020-08-05T14:22-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1092A1130OCCUR Occurrence Indicator Rash REACTOGENICITY SYSTEMIC Y Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-09T17:45 ADAY 8 ADOSE 12020-07-02T10:27-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1092A 1130OCCUR Occurrence Indicator Rash REACTOGENICITY SYSTEMIC Y Y . STUDY SUBJECT.BLINDED TREATMENT 2020-07-11T13:17 ADAY 10 ADOSE 12020-07-02T10:27-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1092A01130OCCUR Occurrence Indicator Rash REACTOGENICITY SYSTEMIC N N . STUDY SUBJECT.BLINDED TREATMENT 2020-07-12T13:49 ADAY 11 ADOSE 12020-07-02T10:27-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1092A@1130OCCUR Occurrence Indicator Rash REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 12020-07-02T10:27-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1092AP1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-09 ADAY 8 ADOSE 12020-07-02T10:27-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1092A`1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-09T17:45 ADAY 8 ADOSE 12020-07-02T10:27-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1092Ap1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-10 ADAY 9 ADOSE 12020-07-02T10:27-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1092A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-11 ADAY 10 ADOSE 12020-07-02T10:27-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1092A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-11T13:17 ADAY 10 ADOSE 12020-07-02T10:27-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1092A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-12 ADAY 11 ADOSE 12020-07-02T10:27-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1092A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-12T13:48 ADAY 11 ADOSE 12020-07-02T10:27-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1092A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-13 ADAY 12 ADOSE 12020-07-02T10:27-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1092A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-14 ADAY 13 ADOSE 12020-07-02T10:27-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1092A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T08:02 ADAY 12 ADOSE 12020-07-02T10:27-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1092A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-14T14:42 ADAY 13 ADOSE 12020-07-02T10:27-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1092B1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 9 ADOSE 12020-07-02T10:27-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1099A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-05 B)DAY 8 ADOSE 22020-07-29T08:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1099A 2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-06 B*DAY 9 ADOSE 22020-07-29T08:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1099A02100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-06T05:16 B*DAY 8 ADOSE 22020-07-29T08:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1099A@2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-06T19:30 B*DAY 9 ADOSE 22020-07-29T08:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1099AP2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-07 B+DAY 10 ADOSE 22020-07-29T08:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1099A`2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-07T21:28 B+DAY 10 ADOSE 22020-07-29T08:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1099Ap2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-08 B,DAY 11 ADOSE 22020-07-29T08:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1099A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-08T19:01 B,DAY 11 ADOSE 22020-07-29T08:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1099A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-09 B-DAY 12 ADOSE 22020-07-29T08:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1099A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-09T21:00 B-DAY 12 ADOSE 22020-07-29T08:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1099A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-10 B.DAY 13 ADOSE 22020-07-29T08:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1099A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-11 B/DAY 14 ADOSE 22020-07-29T08:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1099A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-11T17:50 B/DAY 14 ADOSE 22020-07-29T08:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1099A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 13 ADOSE 22020-07-29T08:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1099A2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 15 ADOSE 22020-07-29T08:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1099B2100SEV Severity/Intensity Arthralgia REACTOGENICITY SYSTEMIC . NOT DONE . .DAY 16 BDOSE 22020-07-29T08:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1099B2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-06T05:15 B*DAY 8 ADOSE 22020-07-29T08:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1099B2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-06T19:29 B*DAY 9 ADOSE 22020-07-29T08:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1099B2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-07T21:28 B+DAY 10 ADOSE 22020-07-29T08:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1099B2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-08T19:01 B,DAY 11 ADOSE 22020-07-29T08:04-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1100A1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-09 ADAY 8 ADOSE 12020-07-02T13:51-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1100A 1080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-09T12:12 ADAY 8 ADOSE 12020-07-02T13:51-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1100A01080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-10T12:31 ADAY 9 ADOSE 12020-07-02T13:51-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1100A@2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-10 B(DAY 8 ADOSE 22020-08-03T10:06-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1100AP2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-10T12:30 B(DAY 8 ADOSE 22020-08-03T10:06-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1100A`2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-08-11 B)DAY 9 ADOSE 22020-08-03T10:06-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1100Ap2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-11T12:16 B)DAY 9 ADOSE 22020-08-03T10:06-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1100A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-12T12:08 B*DAY 10 ADOSE 22020-08-03T10:06-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1100A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-09 ADAY 8 ADOSE 12020-07-02T13:51-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1100A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-09T12:11 ADAY 8 ADOSE 12020-07-02T13:51-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1100A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-10 ADAY 9 ADOSE 12020-07-02T13:51-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1100A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-10T12:30 ADAY 9 ADOSE 12020-07-02T13:51-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1100A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 1/MILD GRADE 1/MILD . INVESTIGATOR .BLINDED TREATMENT 2020-07-11 ADAY 10 ADOSE 12020-07-02T13:51-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1100A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-07-11T12:01 ADAY 10 ADOSE 12020-07-02T13:51-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1100A1070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-07-12T12:31 ADAY 11 ADOSE 12020-07-02T13:51-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1116A2040OCCUR Occurrence Indicator Erythema REACTOGENICITY ADMINISTRATION SITEN N . STUDY SUBJECT.BLINDED TREATMENT 2020-08-06T02:39 B'DAY 8 ADOSE 22020-07-29T12:10-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1117A2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITENONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-19T05:21 B-DAY 8 ADOSE 22020-08-11T15:30-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1119A2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITENONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-18T18:11 B,DAY 8 ADOSE 22020-08-11T07:48-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1120A2030SEV Severity/Intensity Pain REACTOGENICITY ADMINISTRATION SITENONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-05T21:03 B$DAY 8 ADOSE 22020-07-29T14:00-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1129A2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC GRADE 2/MODERATE GRADE 2/MODERATE . INVESTIGATOR .BLINDED TREATMENT 2020-08-10 B(DAY 8 ADOSE 22020-08-03T13:59-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1129A 2080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC SOME INTERFERENCE WITH ACTIVITY SOME INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-10T12:04 B(DAY 8 ADOSE 22020-08-03T13:59-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1129A02080SEV Severity/Intensity Fatigue REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-11T16:23 B)DAY 9 ADOSE 22020-08-03T13:59-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1129A@2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC GRADE 2/MODERATE GRADE 2/MODERATE . INVESTIGATOR .BLINDED TREATMENT 2020-08-10 B(DAY 8 ADOSE 22020-08-03T13:59-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1129AP2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY NO INTERFERENCE WITH ACTIVITY . STUDY SUBJECT.BLINDED TREATMENT 2020-08-10T12:04 B(DAY 8 ADOSE 22020-08-03T13:59-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1129A`2070SEV Severity/Intensity Headache REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-11T16:23 B)DAY 9 ADOSE 22020-08-03T13:59-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1129Ap2110SEV Severity/Intensity Nausea/Vomiting REACTOGENICITY SYSTEMIC GRADE 2/MODERATE GRADE 2/MODERATE . INVESTIGATOR .BLINDED TREATMENT 2020-08-10 B(DAY 8 ADOSE 22020-08-03T13:59-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1129A2110SEV Severity/Intensity Nausea/Vomiting REACTOGENICITY SYSTEMIC NO INTERFERENCE WITH ACTIVITY OR 1-2 EPISODES/24 HOURS NO INTERFERENCE WITH ACTIVITY OR 1-2 EPISODES/24 HOURS . STUDY SUBJECT.BLINDED TREATMENT 2020-08-10T12:04 B(DAY 8 ADOSE 22020-08-03T13:59-P1DmRNA-1273-P201FAmRNA-1273-P201-US208-1129A2110SEV Severity/Intensity Nausea/Vomiting REACTOGENICITY SYSTEMIC NONE NONE . STUDY SUBJECT.BLINDED TREATMENT 2020-08-11T16:23 B)DAY 9 ADOSE 22020-08-03T13:59-P1D